Editas Medicine Croissance future

Future contrôle des critères 1/6

Les bénéfices de Editas Medicine devraient diminuer de 0.3% par an tandis que son chiffre d'affaires annuel devrait croître de 15.2% par an. Le BPA devrait croître de de 13.8% par an. Le rendement des capitaux propres devrait être -187.5% dans 3 ans.

Informations clés

-0.3%

Taux de croissance des bénéfices

13.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	15.2%
Rendement futur des capitaux propres	-187.5%
Couverture par les analystes	Good
Dernière mise à jour	08 Nov 2024

Mises à jour récentes de la croissance future

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

Recent updates

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Nov 20

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:EDIT - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	20	-253	-225	-224	13
12/31/2025	27	-243	-215	-210	18
12/31/2024	41	-221	-150	-143	18
9/30/2024	62	-211	-191	-182	N/A
6/30/2024	67	-193	-172	-165	N/A
3/31/2024	69	-166	-151	-146	N/A
12/31/2023	78	-153	-137	-132	N/A
9/30/2023	25	-195	-156	-152	N/A
6/30/2023	19	-206	-169	-165	N/A
3/31/2023	23	-219	-168	-164	N/A
12/31/2022	20	-220	-181	-177	N/A
9/30/2022	26	-201	-176	-170	N/A
6/30/2022	32	-184	-171	-162	N/A
3/31/2022	26	-186	-174	-164	N/A
12/31/2021	26	-193	-172	-164	N/A
9/30/2021	24	-214	-176	-169	N/A
6/30/2021	81	-167	-189	-183	N/A
3/31/2021	92	-135	-180	-175	N/A
12/31/2020	91	-116	-187	-180	N/A
9/30/2020	92	-91	-106	-99	N/A
6/30/2020	33	-132	-79	-71	N/A
3/31/2020	24	-142	-73	-66	N/A
12/31/2019	21	-134	-47	-41	N/A
9/30/2019	14	-121	-86	-80	N/A
6/30/2019	25	-103	-66	-61	N/A
3/31/2019	30	-108	-57	-52	N/A
12/31/2018	32	-110	-50	-46	N/A
9/30/2018	29	-121	-76	-72	N/A
6/30/2018	21	-132	N/A	-92	N/A
3/31/2018	17	-120	N/A	-102	N/A
12/31/2017	14	-120	N/A	-9	N/A
9/30/2017	11	-124	N/A	2	N/A
6/30/2017	6	-118	N/A	13	N/A
3/31/2017	6	-111	N/A	29	N/A
12/31/2016	6	-97	N/A	-50	N/A
9/30/2016	6	-71	N/A	-45	N/A
6/30/2016	6	-57	N/A	-39	N/A
3/31/2016	2	-86	N/A	-9	N/A
12/31/2015	2	-73	N/A	-5	N/A
9/30/2015	1	-66	N/A	-1	N/A
6/30/2015	0	-62	N/A	9	N/A
3/31/2015	N/A	-17	N/A	-13	N/A
12/31/2014	N/A	-14	N/A	-9	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EDIT devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: EDIT devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: EDIT devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de EDIT ( 15.2% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de EDIT ( 15.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: EDIT devrait être non rentable dans 3 ans.

Editas Medicine Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 78%

Price target decreased by 7.1% to US$13.00

Consensus revenue estimates fall by 13%

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Recent updates

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Consensus revenue estimates increase by 78%

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Price target decreased by 7.1% to US$13.00

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Consensus revenue estimates fall by 13%

New major risk - Revenue and earnings growth

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Insider selling

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline